Roche ：bexobrutideg has been in-licensed for development
Bexobrutideg (NX-5948), a BTK degrader, is the subject of an exclusive licensing agreement announced on June 8 between Roche and Nurix Therapeutics to co-develop the drug in a deal totaling up to $2.3 billion. The collaboration covers clinical development programs in B-cell malignancies, immunology, and neurology.
Under the terms of the agreement, Nurix will receive a $700 million upfront payment and is eligible for development, regulatory, and sales milestone payments, with the total potential transaction value reaching up to $2.3 billion. Development costs will be shared, with Nurix bearing 40% and Roche 60%. The parties will equally split U.S. commercialization profits and losses. Nurix and Roche will co-commercialize bexobrutideg in the U.S. across all indications. Outside the U.S., Roche will lead commercialization, and Nurix will receive tiered royalties ranging from 10% to up to low-twenties percentages.
Bexobrutideg is an oral BTK degrader planned to initiate Phase III clinical trials for chronic lymphocytic leukemia (CLL) in the summer of 2026. Existing clinical data suggest that the product has the potential to become a best-in-class treatment, offering higher efficacy and better tolerability than existing therapies, as well as the potential to overcome resistance mechanisms associated with current standard BTK inhibitors.
According to the press release, BTK-targeting drugs are the leading drug class in the growing non-Hodgkin lymphoma (NHL) and CLL market. The total market size is expected to reach $41 billion by 2031, with BTK inhibitors maintaining sales leadership at approximately $19 billion. This growth is particularly significant in the CLL space, where the market is projected to grow from $12 billion in 2024 to $16 billion by 2035.
Buy bexobrutideg online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
